Ab­b­Vie dives deep­er in­to eye care, pay­ing $370M cash — with a $1.4B sweet­en­er — to part­ner on VEGF gene ther­a­py

Ab­b­Vie is ex­pand­ing the oph­thal­mol­o­gy seg­ment of their pipeline to­day, bag­ging a gene ther­a­py now in piv­otal tri­als for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion for a whop­ping $370 mil­lion in cash and adding $1.38 bil­lion in mile­stone cash as a sweet­en­er. And its new part­ners at Re­genxbio al­so get sup­port for fu­ture tri­al work.

In ex­change, Ab­b­Vie gets to take the lead on the glob­al com­mer­cial­iza­tion ef­fort — if it works — along with de­vel­op­ment work, with Re­genxbio $RGNX jump­ing in along­side in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER